<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">M. Taha</style></author><author><style face="normal" font="default" size="100%">Hedberg,S.T.</style></author><author><style face="normal" font="default" size="100%">Szatanik,M.</style></author><author><style face="normal" font="default" size="100%">Hong,E.</style></author><author><style face="normal" font="default" size="100%">Ruckly,C.</style></author><author><style face="normal" font="default" size="100%">Abad,R.</style></author><author><style face="normal" font="default" size="100%">Sophie Bertrand</style></author><author><style face="normal" font="default" size="100%">Carion,F.</style></author><author><style face="normal" font="default" size="100%">Claus,H.</style></author><author><style face="normal" font="default" size="100%">Corso,A.</style></author><author><style face="normal" font="default" size="100%">Enriquez,R.</style></author><author><style face="normal" font="default" size="100%">Heuberger,S.</style></author><author><style face="normal" font="default" size="100%">Hryniewicz,W.</style></author><author><style face="normal" font="default" size="100%">Jolley,K.A.</style></author><author><style face="normal" font="default" size="100%">Kriz,P.</style></author><author><style face="normal" font="default" size="100%">Mollerach,M.</style></author><author><style face="normal" font="default" size="100%">Musilek,M.</style></author><author><style face="normal" font="default" size="100%">Neri,A.</style></author><author><style face="normal" font="default" size="100%">Olcen,P.</style></author><author><style face="normal" font="default" size="100%">Pana,M.</style></author><author><style face="normal" font="default" size="100%">Skoczynska,A.</style></author><author><style face="normal" font="default" size="100%">P.C. Sorhouet</style></author><author><style face="normal" font="default" size="100%">Stefanelli,P.</style></author><author><style face="normal" font="default" size="100%">Tzanakaki,G.</style></author><author><style face="normal" font="default" size="100%">Unemo,M.</style></author><author><style face="normal" font="default" size="100%">Vazquez,J.A.</style></author><author><style face="normal" font="default" size="100%">Vogel,U.</style></author><author><style face="normal" font="default" size="100%">Wasko,I.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Multicenter study for defining the breakpoint for rifampin resistance in Neisseria meningitidis by rpoB sequencing36888</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrob.Agents Chemother.</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">0</style></keyword><keyword><style  face="normal" font="default" size="100%">2009</style></keyword><keyword><style  face="normal" font="default" size="100%">a</style></keyword><keyword><style  face="normal" font="default" size="100%">Absence</style></keyword><keyword><style  face="normal" font="default" size="100%">acid</style></keyword><keyword><style  face="normal" font="default" size="100%">AFRICAN</style></keyword><keyword><style  face="normal" font="default" size="100%">Agent</style></keyword><keyword><style  face="normal" font="default" size="100%">Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">ALL</style></keyword><keyword><style  face="normal" font="default" size="100%">alleles</style></keyword><keyword><style  face="normal" font="default" size="100%">Amino Acid Sequence</style></keyword><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Anti-Bacterial Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">Argentina</style></keyword><keyword><style  face="normal" font="default" size="100%">article</style></keyword><keyword><style  face="normal" font="default" size="100%">AS</style></keyword><keyword><style  face="normal" font="default" size="100%">at</style></keyword><keyword><style  face="normal" font="default" size="100%">Bacteremia</style></keyword><keyword><style  face="normal" font="default" size="100%">Bacterial Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Clinical</style></keyword><keyword><style  face="normal" font="default" size="100%">CONTACT</style></keyword><keyword><style  face="normal" font="default" size="100%">CONTACTS</style></keyword><keyword><style  face="normal" font="default" size="100%">Cost</style></keyword><keyword><style  face="normal" font="default" size="100%">Countries</style></keyword><keyword><style  face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style  face="normal" font="default" size="100%">data</style></keyword><keyword><style  face="normal" font="default" size="100%">Database</style></keyword><keyword><style  face="normal" font="default" size="100%">Dna</style></keyword><keyword><style  face="normal" font="default" size="100%">drug effects</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Resistance,Bacterial</style></keyword><keyword><style  face="normal" font="default" size="100%">electronic</style></keyword><keyword><style  face="normal" font="default" size="100%">European</style></keyword><keyword><style  face="normal" font="default" size="100%">European countries</style></keyword><keyword><style  face="normal" font="default" size="100%">Failure</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">France</style></keyword><keyword><style  face="normal" font="default" size="100%">gene</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic</style></keyword><keyword><style  face="normal" font="default" size="100%">genetics</style></keyword><keyword><style  face="normal" font="default" size="100%">identification</style></keyword><keyword><style  face="normal" font="default" size="100%">im</style></keyword><keyword><style  face="normal" font="default" size="100%">IS</style></keyword><keyword><style  face="normal" font="default" size="100%">IT</style></keyword><keyword><style  face="normal" font="default" size="100%">journal</style></keyword><keyword><style  face="normal" font="default" size="100%">Laboratories</style></keyword><keyword><style  face="normal" font="default" size="100%">LEVEL</style></keyword><keyword><style  face="normal" font="default" size="100%">levels</style></keyword><keyword><style  face="normal" font="default" size="100%">mice</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice,Inbred BALB C</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice,Transgenic</style></keyword><keyword><style  face="normal" font="default" size="100%">Microbial Sensitivity Tests</style></keyword><keyword><style  face="normal" font="default" size="100%">Molecular Sequence Data</style></keyword><keyword><style  face="normal" font="default" size="100%">Mutation</style></keyword><keyword><style  face="normal" font="default" size="100%">n</style></keyword><keyword><style  face="normal" font="default" size="100%">national</style></keyword><keyword><style  face="normal" font="default" size="100%">Neisseria</style></keyword><keyword><style  face="normal" font="default" size="100%">Neisseria meningitidis</style></keyword><keyword><style  face="normal" font="default" size="100%">paris</style></keyword><keyword><style  face="normal" font="default" size="100%">Patient</style></keyword><keyword><style  face="normal" font="default" size="100%">patients</style></keyword><keyword><style  face="normal" font="default" size="100%">pharmacology</style></keyword><keyword><style  face="normal" font="default" size="100%">Phylogeny</style></keyword><keyword><style  face="normal" font="default" size="100%">prophylaxis</style></keyword><keyword><style  face="normal" font="default" size="100%">protein</style></keyword><keyword><style  face="normal" font="default" size="100%">Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Research</style></keyword><keyword><style  face="normal" font="default" size="100%">Research Support</style></keyword><keyword><style  face="normal" font="default" size="100%">Residue</style></keyword><keyword><style  face="normal" font="default" size="100%">resistance</style></keyword><keyword><style  face="normal" font="default" size="100%">Rifampin</style></keyword><keyword><style  face="normal" font="default" size="100%">SB - IM</style></keyword><keyword><style  face="normal" font="default" size="100%">STANDARDIZATION</style></keyword><keyword><style  face="normal" font="default" size="100%">study</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">0/9/2010</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">3658</style></number><volume><style face="normal" font="default" size="100%">54</style></volume><pages><style face="normal" font="default" size="100%">3651 - 3658</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Identification of clinical isolates of Neisseria meningitidis that are resistant to rifampin is important to avoid prophylaxis failure in contacts of patients, but it is hindered by the absence of a breakpoint for resistance, despite many efforts toward standardization. We examined a large number (n = 392) of clinical meningococcal isolates, spanning 25 years (1984 to 2009), that were collected in 11 European countries, Argentina, and the Central African Republic. The collection comprises all clinical isolates with MICs of &gt; or = 0.25 mg/liter (n = 161) received by the national reference laboratories for meningococci in the participating countries. Representative isolates displaying rifampin MICs of &lt; 0.25 mg/liter were also examined (n = 231). Typing of isolates was performed, and a 660-bp DNA fragment of the rpoB gene was sequenced. Sequences differing by at least one nucleotide were defined as unique rpoB alleles. The geometric mean of the MICs was calculated for isolates displaying the same allele. The clinical isolates displaying rifampin MICs of &gt; 1 mg/liter possessed rpoB alleles with nonsynonymous mutations at four critical amino acid residues, D542, H552, S548, and S557, that were absent in the alleles found in all isolates with MICs of &lt; or = 1 mg/liter. Rifampin-susceptible isolates could be defined as those with MICs of &lt; or = 1 mg/liter. The rpoB allele sequence and isolate data have been incorporated into the PubMLST Neisseria database (http://pubmlst.org/neisseria/). The rifampin-resistant isolates belonged to diverse genetic lineages and were associated with lower levels of bacteremia and inflammatory cytokines in mice. This biological cost may explain the lack of clonal expansion of these isolates</style></abstract><issue><style face="normal" font="default" size="100%">9</style></issue><custom1><style face="normal" font="default" size="100%">38380</style></custom1><section><style face="normal" font="default" size="100%">3651</style></section></record></records></xml>